Eagle Pharmaceuticals Stock Forecast, Price & News

Wall Street analysts have given Eagle Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Eagle Pharmaceuticals.

Eagle Pharmaceuticals will be holding an earnings conference call on Monday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 402-220-7352 with passcode "EGRXQ221".

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings data on Monday, May, 10th. The specialty pharmaceutical company reported $0.24 EPS for the quarter, topping the Zacks' consensus estimate of $0.20 by $0.04. The specialty pharmaceutical company earned $41.25 million during the quarter, compared to analysts' expectations of $45.67 million. Eagle Pharmaceuticals had a net margin of 7.89% and a trailing twelve-month return on equity of 7.87%.
View Eagle Pharmaceuticals' earnings history.

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 16.9% and is now trading at $45.67.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Eagle Pharmaceuticals include Rocket Pharmaceuticals (RCKT), Atea Pharmaceuticals (AVIR), Zentalis Pharmaceuticals (ZNTL), ATA (ATAI), Cytokinetics (CYTK), Arcus Biosciences (RCUS), Revance Therapeutics (RVNC), Morphic (MORF), Protagonist Therapeutics (PTGX), Global Blood Therapeutics (GBT), Ironwood Pharmaceuticals (IRWD), Organogenesis (ORGO), Amarin (AMRN), Deciphera Pharmaceuticals (DCPH) and Axsome Therapeutics (AXSM).
View all of EGRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Chartwell Investment Partners LLC (1.49%), Scout Investments Inc. (1.35%), Russell Investments Group Ltd. (0.33%), Alliancebernstein L.P. (0.32%), Dupont Capital Management Corp (0.19%) and Exchange Traded Concepts LLC (0.17%).
View institutional ownership trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Chartwell Investment Partners LLC, and Envestnet Asset Management Inc..
View insider buying and selling activity for Eagle Pharmaceuticals or view top insider-selling stocks.

EGRX stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Dupont Capital Management Corp, Ziegler Capital Management LLC, Alliancebernstein L.P., Victory Capital Management Inc., Fisher Asset Management LLC, Exchange Traded Concepts LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Eagle Pharmaceuticals or or view top insider-buying stocks.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EGRX stock can currently be purchased for approximately $45.67.

Eagle Pharmaceuticals has a market capitalization of $598.73 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.87 on an earnings per share basis.

Eagle Pharmaceuticals employs 106 workers across the globe.

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]